Evaluation of commercial antisera for serotyping heat-labile antigens of Campylobacter jejuni and Campylobacter coli.
Commercial antisera for serotyping 22 heat-labile antigens of Campylobacter jejuni and Campylobacter coli were evaluated by using 66 isolates from human and nonhuman sources. Test results were compared with results of tests using antisera produced at the Centers for Disease Control (CDC), Atlanta, Ga. All strains (three isolates of each of the 22 serotypes) were typeable with the CDC antisera. Of 66 test strains, 39 (59%) were typed as the same serotype with both sets of antisera. Twenty-four strains (36%), including two heat-labile serotype reference strains, were nonreactive with the commercial antisera, and three strains (4.5%) were typed as serotypes different from those obtained with CDC antisera. Five of the 22 commercial antisera correctly serotyped all homologous strains. Our study indicated that two polyvalent antiserum pools, 7 unabsorbed antisera, and 16 absorbed monovalent antisera are weak and need modification to enhance their antibody titers. Further studies are necessary to explain the antigenic change to a different serotype in three strains.
Nicholson
M A
MA
Enteric Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333.
Patton
C M
CM
D000818:Animals; D000942:Antigens, Bacterial / Q000032:analysis*; D002169:Campylobacter Infections / Q000382:microbiology; D017000:Campylobacter coli / Q000145:classification* / Q000276:immunology; D016123:Campylobacter jejuni / Q000145:classification* / Q000276:immunology; D006801:Humans; D007106:Immune Sera / Q000276:immunology*; D012703:Serotyping
D000942:Antigens, Bacterial; D007106:Immune Sera